Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

CEO

ISIN

US36322Q2066

Listings

0 Comments

Share your thoughts

FAQ

What is Galecto stock price today?▼

The current price of GLTO.BOATS is $26.71 USD — it has increased by +6.63% in the past 24 hours. Watch Galecto stock price performance more closely on the chart.

What is Galecto stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Galecto stocks are traded under the ticker GLTO.BOATS.

What is Galecto market cap?▼

Today Galecto has the market capitalization of 35.44M

When is the next Galecto earnings date?▼

Galecto is going to release the next earnings report on April 24, 2026.

What were Galecto earnings last quarter?▼

GLTO.BOATS earnings for the last quarter are -2.36 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Galecto revenue for the last year?▼

Galecto revenue for the last year amounts to 0 USD.

What is Galecto net income for the last year?▼

GLTO.BOATS net income for the last year is -42.88M USD.

When did Galecto complete a stock split?▼

Galecto has not had any recent stock splits.